SCHEMBL6427323

SCHEMBL6427323

O=C1N=C(NC2CC3C=CC2C3)SC1CC(=O)N1CCc2ccccc2C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.40
ALDH1A1 P00352 5/20 0.39
MAPT P10636 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 3/20 0.38
TAAR1 Q96RJ0 1/20 0.38
HTT P42858 1/20 0.38
ALOX12 P18054 1/20 0.38
DPP8 Q6V1X1 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC11 Q96DB2 1/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6427696 0.93 DPP8 (0.34) DPP4ALDH1A1TDP1KDM4EDPP8
SCHEMBL6426277 0.86 ALDH1A1 (0.43) ALDH1A1MAPTNPC1RAB9AMEN1
SCHEMBL6507788 0.83 ALDH1A1 (0.39) ALDH1A1MAPTKDM4EMEN1KMT2A
SCHEMBL6504880 0.83 TSHR (0.42) ALDH1A1TDP1KDM4EMEN1KMT2A
SCHEMBL14344793 0.83 TSHR (0.42) ALDH1A1TDP1KDM4EMEN1KMT2A
SCHEMBL6428776 0.83 ALDH1A1 (0.49) DPP4ALDH1A1MAPTTDP1KDM4E
SCHEMBL6503292 0.81 ALDH1A1 (0.35) ALDH1A1MAPTTDP1KDM4ETAAR1
SCHEMBL6393517 0.81 ALDH1A1 (0.55) DPP4ALDH1A1MAPTTDP1KDM4E
SCHEMBL6427188 0.80 ALDH1A1 (0.57) DPP4ALDH1A1MAPTTDP1KDM4E
SCHEMBL6426510 0.80 ALDH1A1 (0.57) DPP4ALDH1A1MAPTTDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US claimed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO claimed
US-20050239853-A1 New compounds BIOVITRUM AB (SE) 2005-10-27 US disclosed
WO-2005075471-A2 THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS BIOVITRUM AB (SE) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239853-A1 New compounds HSD11B1, CYP11B1, HSD3B1 DPP4 1365/4885ALDH1A1 67/4885MAPT 3607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.